story of the week
Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 Jan 22;[EPub Ahead of Print], HS Rugo, SA Im, F Cardoso, J Cortés, G Curigliano, A Musolino, MD Pegram, GS Wright, C Saura, S Escrivá-de-Romaní, M De Laurentiis, C Levy, U Brown-Glaberman, JM Ferrero, M de Boer, SB Kim, K Petráková, DA Yardley, O Freedman, EH Jakobsen, B Kaufman, R Yerushalmi, PA Fasching, JL Nordstrom, E Bonvini, S Koenig, S Edlich, S Hong, EP Rock, WJ GradisharFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.